How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
Metrics: PDF 2465 views | HTML 2060 views | ?
Sara Pusceddu1,2, Filippo De Braud1,2, Giuseppe Lo Russo1,2, Laura Concas1,2, Daniela Femia1,2, Claudio Vernieri1,2, Alice Indini1,2, Barbara Formisano1,2 and Roberto Buzzoni1,2
1 Medical Oncology Department, ENETs Center of Excellence, Milan, Italy
2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Sara Pusceddu, email:
Keywords: everolimus, neuroendocrine tumors
Received: December 14, 2015 Accepted: March 10, 2016 Published: April 05, 2016
In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.
In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.